JUN 08, 2016 2:00 PM PDT

Alteration of "Programmed Death Ligand" Promotes Cancer Metastasis

WRITTEN BY: Kara Marker
There’s a protein that signals the immune system not to kill certain cells. This action could be preventing autoimmune disease, or it could be harnessed by cancer cells to inhibit the immune system when it should be fighting back. A new study from Kyoto University in Japan uncovered genetic alterations to the protein that increase production in favor of growing tumors, and they plan to counteract these changes to prevent cancer growth.

Image credit: Kyoto University
 
The protein at the center of this study is called programmed-death ligand 1, or PD-L1. The genetic mutation that occurs and promotes cancer growth disrupts normal structure of the gene’s 3’ untranslated region of the gene the codes for the PD-L1 protein. The researchers plan to continue investigating these structural changes to understand how cancer cells can grow uncontrollably with the immune system inhibited by PD-L1 activity.
 
There are very effective treatment options using antibodies that target either PD-L1 or its receptor, PD-1, that exists on the surface of immune cells like T lymphocytes. However, these therapies are just as expensive as they are effective. In order to create treatment options that are both effective and affordable, the researchers from Kyoto University set out to identify cancer biomarkers to pinpoint which patients would respond especially well to immune checkpoint inhibitor drugs like PD-L1 targeting antibodies.
 
Of the 27 percent of patients with adult T cell leukemia or lymphoma who had genetic alterations of the 3’ untranslated region of the PD-L1 gene, the researchers used next-generation genetic sequencing data in attempt to identify the source of alteration. The researchers also sequenced data from over ten thousand samples from the Cancer Genome Atlas, finding similar alterations in other cancer types, including malignant lymphoma, stomach cancer, and cervical cancer.
 
The Cancer Genome Atlas is a collaboration between the National Cancer Institute and the National Human Genome Research Institute dedicated to providing comprehensive maps of key genomic changes in over 30 types of cancer.
 
The researchers were able to generate the same genetic alterations of the 3’ untranslated region of the PD-L1 gene in human and mouse cells using CRISPR-Cas9, a genome editing system using short palindromic repeats that target DNA based on sequence complementarity. Just like their previous findings, these cells had an elevated level of PD-L1 expression, and cancer cells were able to evade an immune attack.
 
On tap next for this research group is to test the structural genetic alteration as a genetic marker for cancer in a phase II clinical trial.
 
“Once we confirm the significance of these genetic alterations, it’ll be a game changer for immunotherapy in cancer,” said senior author of the study, Seishi Ogawa, PhD.
 

 
Sources: Kyoto University, New England Biolabs, Nature, Cancer Genome Atlas
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAY 17, 2021
Cell & Molecular Biology
Survey Results: Where Is Pluripotent Stem Cell Research Now?
MAY 17, 2021
Survey Results: Where Is Pluripotent Stem Cell Research Now?
Human pluripotent stem cell (hPSC) lines are now commonly used across the globe. In the lab, researchers rely on hPSCs t ...
JUN 10, 2021
Immunology
Decoding the Immune System's Language
JUN 10, 2021
Decoding the Immune System's Language
Scientists at UCLA have decoded the “vocabulary” of immune cells—six distinct signals used as flares t ...
JUN 11, 2021
Cannabis Sciences
Does Cannabis Interact with the COVID Vaccine?
JUN 11, 2021
Does Cannabis Interact with the COVID Vaccine?
As of June 10th 2021, 43% of people in the US aged 12 and over have been fully vaccinated for COVID-19, with 5 ...
JUL 08, 2021
Cancer
Activating p53 May Boost Efficacy of Cancer Immunotherapy
JUL 08, 2021
Activating p53 May Boost Efficacy of Cancer Immunotherapy
Pharmacological activation of the p53 protein in cancer cells leads to an anti-tumor immune response in lab tests. These ...
JUL 18, 2021
Cancer
Light Alcohol Use Linked to Higher Cancer Risk
JUL 18, 2021
Light Alcohol Use Linked to Higher Cancer Risk
Moderate alcohol use is linked to a substantially higher risk of several forms of cancer, including breast, colon, and o ...
JUL 20, 2021
Coronavirus
Pregnant and lactating people can pass COVID-19 antibodies from the vaccine
JUL 20, 2021
Pregnant and lactating people can pass COVID-19 antibodies from the vaccine
New research found that both pregnant and lactating people who receive the COVID-19 vaccine can pass antibodies to their ...
Loading Comments...